Efficacy and Safety of SurgiFill™ on Spinal Fusion

Phase 4

• Conditions: Fusion of Spine (Disease); Spinal Fusion Acquired
• Interventions: Procedure: Spinal Fusion; Device: SurgiFill™

• Registration Number: NCT02466048
• Lead Sponsor: Sewon Cellontech Co., Ltd.

Brief Summary

This study was designed to investigate the safety and efficacy of SurgiFill™, a bone grafting material, in patients with spinal fusion.

Detailed Description

This study is an open-trial study. The study will be explained to the subjects and they voluntarily agreed to participate in it. Their eligibility to participate in the study will be checked, either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the area for the study group, autogenous bones and SurgiFillTM will be grafted; and in the area for the control group, only the autogenous bones will be grafted. They will be asked to follow the guidelines of the investigators during the study and to visit the hospital seven times, including for screening. At each visit, the subjects undergo an examination with doctors, a CT scan, a X-ray, and a SPECT/CT procedure to evaluate the safety and efficacy of SurgiFill™. (\*If the subject gets surgery on the screening date, the total number of his or her visits will be six).

Study Timeline

• Study Start: 2013-08
• Status Verified: 2015-06
• Study First Submitted: 2015-06-01
• Study First Submitted QC: 2015-06-04
• Last Update Submitted: 2015-06-04
• Study First Posted: 2015-06-09
• Last Update Posted: 2015-06-09
• Primary Completion: 2015-10
• Study Completion: 2016-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Patients who require spinal fusion
2. Adult patients aged 20 or older
3. Patients who voluntarily agreed to participate in this study and signed the informed consent form, and who do not fall into any of the exclusion criteria

Exclusion Criteria

1. Patients or their family members with a history of an, or an ongoing, autoimmune disease
2. Patients with a history of anaphylactic response
3. Patients with hypersensitivity to grafting materials
4. Patients with hypersensitivity to pig protein
5. Patients with osteomyelitis in the surgery area
6. Patients who are pregnant, breastfeeding, or planning to become pregnant
7. Patients with other tumors or a non-curable disease
8. Patients with a history of radiation therapy or cancer treatment within two years (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
9. Patients with diabetes (Those who maintain a normal blood sugar level and did not develop complications may receive the SurgiFill™ injection based on the investigator's judgment, but the doctor's confirmation is required.)
10. Patients with an infection that required hospitalization for antibiotics or the administration of antiseptic agents
11. Patients who have been undergoing adrenocortical hormone therapy (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
12. Patients with liver, heart, or kidney disease (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment. Hypertension patients are allowed.)
13. Patients who had been infected with a virus (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
14. Patients with chronic renal failure or an endocrine system disease (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.)
15. Patients who are considered inappropriate for participation in this study due to their condition (e.g., a mental illness) based on the investigator's judgment
16. Patients who had participated in another clinical trial (limited to those who participated in other studies on fracture within the last six months.)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SurgiFill™ on Spinal Fusion	SurgiFill™	In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
SurgiFill™ on Spinal Fusion	Spinal Fusion	In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
Autograft on Spinal Fusion	Spinal Fusion	In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.

Primary Outcome Measures

Name	Time	Method
Volume change of bony fusion mass in the CT	1week, 6month, and 12month	A CT scan shall be conducted one week, and six and 12 months, post-operatively to calculate and record the bone integration volume. The changes in the bone integration volume shown in the CT images shall be compared and analyzed. In other words, the mean values of the experiment group's bone integration volume shown in CT images 1week, six and 12 months post-operatively shall be compared and analyzed.

Secondary Outcome Measures

Name	Time	Method
Degree change of bony fusion mass in the X-ray	1month, 3month, 6month, and 12month	A radiography shall be conducted one, three, six, and 12 months post-operatively, and at the additional unscheduled visits, and the PIs from different institutions (i.e., the Seoul St. Mary's PI and the Daejon St. Mary's PI) shall cross-evaluate the results. The mean values of the experiment group's surgical site bone integration level shown in X-ray images one, three, six and 12 months post-operatively shall be compared and analyzed.
VAS Score change of Back pain questionnaire	screening, 6month and 12 month	The level of the pain (i.e., the lumbar pain and the pain radiating to the upper and lower extremities) shall be recorded using the VAS before the spondylodesis, and at six and 12 months post-operatively.
Value of ROI(Region of interest) in the SPECT/CT	3month	The osteoblastic activity levels at the surgical sites of the experiment and control groups shall be compared at three months post-operatively.
ODI Score change of Back pain questionnaire	screening, 6month and 12 month	Using the ODI score from the ODQ, the disturbances in the daily activities associated with the lumbar pain shall be compared before the spondylodesis, and at six and 12 months post-operatively.

Trial Locations

Locations (2)

The Catholic Univ. of Korea, Daejeon St. Mary's Hospital; 🇰🇷 Daejeon, Korea, Republic of

The Catholic Univ. of Korea, Seoul St. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of